Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
NCT06409767 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2224
Last updated 2025-09-24
Summary
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in increased mortality. This encourages great alertness although not all patients require close monitoring. It is therefore critical to identify which patients are the most at risk for clinical deterioration to consider increased surveillance in these patients. The benefit of early intensive care unit (ICU) admission, as soon as the first signs of organ dysfunction appear, must also be clarified. Such an intervention could increase survival of patients by close monitoring and early initiation of organ-specific interventions but could also be responsible for anxiety and increased use of ICU resources.
Many teams have analyzed the impact of early warning systems (EWS) including vital signs to detect organ dysfunction early on. It has been shown that these EWS could positively impact survival in many medical fields (pre-hospital, medicine or surgery departments). A few retrospective studies have explored the impact of EWS in hematology, with overall good prediction for ICU admission and mortality. Until now, it has however not been formally demonstrated that early ICU admission, as soon as the first signs of organ dysfunction appear, could benefit patients with hematologic malignancies. A randomized controlled trial studying the impact of early intervention would clarify the role of such a strategy.
In this study, the investigators will prospectively evaluate the implementation of the National Early Warning Score (NEWS), with systematic referral to the ICU in high-score patients, to improve the survival of patients receiving intensive chemotherapy in ten academic centers. This score is one of the most performant and most frequently used to predict organ failure. Its calculation only requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. The investigators will therefore study the impact of ICU admission in patients with high NEWS in a randomized, controlled trial. A cluster randomization is planned in which the centers will be randomized between usual care (control group) and interventional care with transfer to the ICU in the event of a NEWS score ≥7 (interventional group). Each parameter used to calculate the NEWS will be collected at least three times a day by the attending nurse.
Conditions
Interventions
- OTHER
-
Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.
The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
Sponsors & Collaborators
-
University Hospital, Angers
lead OTHER_GOV
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-10
- Primary Completion
- 2028-04-11
- Completion
- 2028-07-11
Countries
- France
Study Locations
More Related Trials
-
Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy
NCT03434795 ·Status: COMPLETED
-
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
NCT01813721 ·Status: COMPLETED
-
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
NCT02393248 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
NCT02178475 ·Status: COMPLETED
-
Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
NCT00875004 ·Status: TERMINATED ·Phase: NA
-
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
NCT04662892 ·Status: UNKNOWN
-
Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced
NCT00210002 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
NCT00883181 ·Status: COMPLETED
-
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
NCT00540696 ·Status: COMPLETED ·Phase: PHASE2
-
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
NCT04477616 ·Status: COMPLETED ·Phase: PHASE2
-
Shared Health Information System for Febrile Neutropenia
NCT03087227 ·Status: COMPLETED ·Phase: NA
-
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
NCT00036023 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04009941 ·Status: COMPLETED ·Phase: PHASE4
-
Profile Fecal Analysis of Neutropenic Enterocolitis
NCT04438278 ·Status: UNKNOWN
-
Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program
NCT04557709 ·Status: WITHDRAWN
-
The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia
NCT02761460 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin
NCT02841722 ·Status: COMPLETED ·Phase: NA
-
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
NCT03618810 ·Status: UNKNOWN
-
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
NCT00216541 ·Status: COMPLETED ·Phase: PHASE4
-
Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
NCT00559195 ·Status: COMPLETED ·Phase: PHASE2
-
The Potential of HemoScreen for Monitoring Blood Values in Cancer Patients at Home
NCT04543734 ·Status: COMPLETED
-
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
NCT03846414 ·Status: UNKNOWN
-
Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia
NCT04910698 ·Status: COMPLETED
-
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
NCT00111137 ·Status: COMPLETED ·Phase: PHASE3
-
Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia
NCT03182465 ·Status: TERMINATED ·Phase: NA